Colgate-Palmolive Q2 2021 net sales rise despite ‘complicated year’

By Kacey Culliney

- Last updated on GMT

Q2 net sales rose in all regions, except North America, with a strong spike in Europe, Africa and Eurasia [Getty Images]
Q2 net sales rose in all regions, except North America, with a strong spike in Europe, Africa and Eurasia [Getty Images]

Related tags Colgate-palmolive financial results Oral care Personal care COVID-19 Europe Raw material costs

Personal care giant Colgate-Palmolive has reported a net sales rise for the second quarter (Q2) of fiscal 2021, with a particularly strong performance in Europe, Africa and Eurasia.

Last week, Colgate-Palmolive pulled in net sales of €3.59bn ($4.26bn) for the second quarter (Q2) of 2021, up 9.5% on the previous year – the highest net sales increase for the company in almost ten years. Net income attributable to Colgate-Palmolive for the quarter sat at €593.8m ($708m) and for the first half (H1) of 2021, net sales tallied up at €7.26bn ($8.6bn), a 7.6% rise on the previous year.

Regionally, Europe and Africa/Eurasia performed the strongest with net sales up 15% and 15.5%, respectively. In Europe, strong organic sales growth was led by the UK, Germany, Poland and the Nordic region and in Africa/Eurasia by Turkey, Nigeria and Russia.

In Latin America – the company’s largest sales region alongside North America – net sales rose 12.5%, with strong performances in Brazil and Mexico, and in Asia Pacific net sales were up 7.5%. Net sales declined 4% in North America, largely due to organic sales declines in personal care and home care.

‘Strong growth’ despite ongoing volatility

Noel Wallace, chairman, president and CEO of Colgate-Palmolive, said the company’s “strong growth momentum”​ had clearly continued during Q2, despite “significant volatility”.

“Despite significant raw material and logistics cost headwinds, we delivered another quarter of increased operating profit, net income and earnings per share on a Base Business basis,” ​Wallace said.

And he said the “difficult cost environment”​ was set to continue into the second half of 2021, along with other challenges.

“As we look around the world, there is still much uncertainty stemming from the COVID-19 pandemic, including volatility in consumer demand and currencies and supply chain disruptions. In the face of these challenges, Colgate people everywhere remain committed to achieving our business goals by driving premium innovation, executing with agility and leveraging digital in all areas of our business.”

John Faucher, chief investor relations officer, agreed. Speaking to analysts on the company’s earnings call, Faucher said: “We expect that all of these factors will continue to impact our business through the second half of this year. Because of that, we remain focused on delivering impactful innovation, leveraging our revenue growth management capabilities to deliver on pricing and driving productivity up and down the income statement.”

Colgate-Palmolive said it had maintained its full-year 2021 guidance, with net sales still expected to grow 4-7%. “I am confident that our investment choices and growth strategies will help us manage through this difficult time,”​ Wallace said.

Related news

Show more

Related products

show more

See our latest innovations in personal care

See our latest innovations in personal care

Content provided by Covation Bio™ PDO | 02-Apr-2024 | White Paper

At CovationBio PDO, we’re helping the world achieve its sustainability goals by enabling better performing, better-for-the planet products across a range...

Collagen Reimagined, Discover Biodesigned Type XXI

Collagen Reimagined, Discover Biodesigned Type XXI

Content provided by Geltor | 20-Mar-2024 | Product Brochure

Collagen is the body’s most abundant protein and a mainstream ingredient for beauty. Type XXI collagen transcends a common protein into a powerful bioactive

Empowering natural barrier function for future-proof skin

Empowering natural barrier function for future-proof skin

Content provided by Lucas Meyer Cosmetics | 14-Mar-2024 | White Paper

Corneopeptyl™ is a new patented peptide biomimetic to the LCE6A protein, obtained by green chemistry-based synthesis. By mimicking the LCE6A protein activity,...

Related suppliers

Follow us

Products

View more

Podcast

Beauty 4.0 Podcast